Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26099346 | 1.00 | ATM (0.32) | ATMNOS2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL26099348 | 1.00 | ATM (0.32) | ATMNOS2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL26918754 | 0.78 | CHRNB2 (0.30) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL22235569 | 0.77 | CHRNB2 (0.42) | ATMNOS2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL13778882 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL31099330 | 0.74 | CYP2D6 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL2437352 | 0.73 | EPHX1 (0.34) | ATM | |
| Hydrochloric Acid SCHEMBL19717784 | 0.73 | — | — | |
| SCHEMBL29244684 | 0.71 | IRAK4 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL23364994 | 0.71 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115916765-B | Pyridine or pyrimidine derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-118786118-A | Antimicrobial compounds and methods | 库扎环球有限责任公司 | 2024-10-15 | — | — | CN | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | ATM 3611/4885NOS2 2703/4885CHRNB2 504/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | ATM 3611/4885NOS2 2703/4885CHRNB2 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.